Stocktoria
Health Catalyst, Inc. HCAT
Health Catalyst, Inc. (HCAT) earns a Piotroski F-score of 5/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $311.1M at a -57.2% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Services · percentile among 982 companies
Percentile vs other Services companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 5/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.159 |
| Retained earnings / assets | -2.715 |
| EBIT / assets | -0.32 |
| Equity / liabilities | 0.957 |
Sector peers · similar-size Services companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| HCAT | Health Catalyst, Inc. | 5/9 | -8.96 | — | +1.5% |
| HSTM | HEALTHSTREAM INC | 5/9 | 3.21 | 42.6 | +4.3% |
| PUBM | PubMatic, Inc. | 5/9 | 2.55 | — | -2.9% |
| SMWB | SIMILARWEB LTD. | 4/9 | -6.63 | — | +13.1% |
| YALA | Yalla Group Ltd | 4/9 | 17.01 | 5.5 | +0.7% |
| DSP | Viant Technology Inc. | 5/9 | 4.2 | 92.5 | +19% |
| NXDR | Nextdoor Holdings, Inc. | 4/9 | 6.62 | — | +4.2% |
About Health Catalyst, Inc.
Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations in the United States. The company operates in two segments: Technology and Professional Services. It offers ignite data and analytics platform that provides clients a single comprehensive environment to integrate and organize data from their disparate software systems; and applications, a software analytics applications build for ignite platform to analyze clients face across clinical improvement, revenue and cost improvement, ambulatory operations, measures and registries, and data and analytics. The company also provides expertise solutions comprising data and analytics, domain expertise and education, tech-enabled managed, and implementation services; and opportunity analysis and prioritization, data governance, data modeling and analysis, quality and process improvement strategy, cost accounting, data abstraction, and population health strategies. It serves academic medical centers, integrated delivery networks, community hospitals, large physician practices, accountable care organizations, health information exchanges, health insurers, life science organizations, healthcare technology vendors, and other risk-bearing entities. The company was formerly known as HQC Holdings, Inc. and changed its name to Health Catalyst, Inc. in March 2017. Health Catalyst, Inc. was founded in 2008 and is headquartered in South Jordan, Utah.
FAQ
Is HCAT financially healthy?
Health Catalyst, Inc.'s Piotroski F-score is 5/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does HCAT pay a dividend?
No, Health Catalyst, Inc. does not currently pay a dividend.
How profitable is HCAT?
In FY2025, Health Catalyst, Inc. had a net margin of -57.2% and a return on equity of -72.4%.
What is the analyst price target for HCAT?
The average Wall-Street price target for Health Catalyst, Inc. is $1.90, about 6.1% above the recent price, from 5 analysts (consensus: buy).
Is HCAT a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Health Catalyst, Inc.: a Piotroski F-score of 5/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.